Phenotypic Implications of CYP2C19*4 and*4B Detection in the General Population

被引：0
|
作者：
Borgman, M. P. [1 ]
Reynolds, K. K. [1 ]
Valdes, R. [1 ]
Linder, M. W. [1 ]
机构：
[1] PGXL Labs, Louisville, KY USA
来源：
JOURNAL OF MOLECULAR DIAGNOSTICS | 2013年 / 15卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
引用
收藏
页码：857 / 857
页数：1
相关论文
共 50 条
  • [31] Pharmacogenetic Expression of CYP2C19 in a Pediatric Population
    Pierre-Francois, Marie Josette Deborah
    Gagne, Vincent
    Brukner, Ivan
    Krajinovic, Maja
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (09):
  • [32] Genetic Polymorphism of CYP2C19 in Pakistani Population
    Riaz, Sana
    Din, Sadia Muhammad
    Tareen, Muhammad Usman
    Tariq, Fizza
    Latif, Yusra
    Siddiqi, Saima
    Sultan, Aneesa
    Mansoor, Atika
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2019, 18 (02): : 1097 - 1102
  • [33] Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population
    Xie, HG
    Huang, SL
    Xu, ZH
    Xiao, XS
    He, N
    Zhou, HH
    PHARMACOGENETICS, 1997, 7 (02): : 115 - 119
  • [34] CYP2C19 genotype and S-mephenytoin 4′-hydroxylation phenotype in a Chinese Dai population
    Nan He
    Feng-Xiang Yan
    Song-Lin Huang
    Wei Wang
    Zhou-Sheng Xiao
    Zhao-Qian Liu
    Hong-Hao Zhou
    European Journal of Clinical Pharmacology, 2002, 58 : 15 - 18
  • [35] CYP2C19 genotype and S-mephenytoin 4′-hydroxylation phenotype in a Chinese Dai population
    He, N
    Yan, FX
    Huang, SL
    Wang, W
    Xiao, ZS
    Liu, ZQ
    Zhou, HH
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (01) : 15 - 18
  • [36] Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro
    Stage, Tore Bjerregaard
    Graff, Magnus
    Wong, Susan
    Rasmussen, Louise Ladebo
    Nielsen, Flemming
    Pottegard, Anton
    Brosen, Kim
    Kroetz, Deanna L.
    Khojasteh, Cyrus
    Damkier, Per
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (03) : 510 - 519
  • [37] A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2, and CYP2C19*3 alleles involving time-resolved fluorometry
    Bathum, L
    Hansen, TS
    Horder, M
    Brosen, K
    THERAPEUTIC DRUG MONITORING, 1998, 20 (01) : 1 - 6
  • [38] High CYP2C19 phenotypic variability in gastrointestinal cancer patients
    Burns, K. E.
    Lo, W. -Y.
    Findlay, M. P.
    Sharples, K.
    Laking, G.
    Helsby, N. A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (01) : 195 - 204
  • [39] High CYP2C19 phenotypic variability in gastrointestinal cancer patients
    K. E. Burns
    W.-Y. Lo
    M. P. Findlay
    K. Sharples
    G. Laking
    N. A. Helsby
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 195 - 204
  • [40] Pharmacodynamic and cytogenetic evaluation in CYP2C19*2 and CYP2C19*3 allelomorphism in South Indian population with clopidogrel therapy
    Tantray, Javeed Ahmad
    Reddy, K. Pratap
    Jamil, Kaiser
    Kumar, Y. Shiva
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 229 : 113 - 118
12345